In this study, we determined in vivo morphologic effects of continuous intravenous infusion of recombinant human epidermal growth factor (EGF) in adult Wistar rats. The EGF used consisted of the amino acid residues 1-48 of the human 53-amino-acid EGF molecule, purified from transfected Escherichia coli. Doses of 25, 100, or 250 pg/kg body weight were administered using Harvard digital syringe infusion pumps for 4 weeks. At necropsy, the submandibular salivary glands, Harderian glands, liver, kidneys (females only), and ovaries were enlarged and urinary bladders were thickened in 100-and 250-pglkg rats. Numerous tissues of the 100-and 250-pglkg rats contained hyperplastic epithelial cells, and selected organs also had mesenchymal cell proliferation. Epithelial proliferation was most pronounced in the trachea, nasal cavity, nasolacrimal duct, tongue, stomach, small intestine, large intestine, urinary tract, salivary gland ducts, and Harderian gland. Periportal hepatocytes were hypertrophic, correlating with increased liver weight. In addition, mesenchymal cell proliferation was evident in the gastric mucosa lamina propria and in heart valves in 100-and 25O-&kg rats. Increased ovarian weight correlated with increased number and size of corpora lutea and an increased incidence of luteal cysts. Continuous systemic exposure of adult Wistar rats to high doses of EGF resulted in generalized epithelial hyperplasia and tissue-selective mesenchymal proliferation.
Epidermal growth factor (EGF) is a natural peptide, originally isolated from mouse salivary gland7J6 and human urine.4 In the rat and human, EGF is most commonly found in duodenal Brunner's glands, salivary glands, nasal serous glands, Paneth cells, and renal tubular cells. 37 The predominant biological effect of EGF is mitogenesis of epithelium and to a lesser extent of some mesenchymal cell population^.^ Previous in vitro studies of rat tissues have demonstrated EGFinduced proliferation of hepatocytes, l 9 malignant ~r o t h e l i u r n ,~~ and smooth muscle cells and dermal fibroblast^^^ and increased survival of salivary gland acinar-intercalated duct c~m p l e x e s .~~ EGF-induced proliferation has also been found in in vivo studies involving the gastric and intestinal mucosa11.15 and urinary bladder ~r o t h e l i u m~~ and in hepatic parenchyma following partial h e p a t e~t o m y ,~~ but detailed histomorphologic descriptions of EGF-induced changes have not been published.
Epidermal growth factor may promote epithelial regeneration following injury, as indicated by several animal models, such as esophageal ulcers and strictures in pigs,25 gastric and intestinal mucosal repair following burn injury in mice,48 gastric cytoprotection following chemically induced ulceration in rat^,^^,^^ experimental colitis in rats,38 and renal function recovery following ischemic or chemically induced renal i n j~r y .~J~ Recombinant human EGF (rhEGF), having biological properties similar to those of endogenous human EGF,40 may be valuable for potential therapeutic applications.
The purpose of this study was to characterize morphologic effects of a 48-amino-acid fraction of rhEGF (rhEGF,,,), which was continuously administered intravenously over a 4-week period to adult Wistar rats. Target tissues of EGF-mediated effects included epithelium of the gastrointestinal, urinary, and respiratory systems and selected mesenchymal cell populations.
Materials and Methods

Test compound
The rhEGF,,, is a fragment of human EGF composed of residues 1-48 purified from transfected Escherichia coli. The amino acid sequence of this peptide is Asp(NH,)-Ser-Asp-Ser-Glu-Cys-Pro-Leu-Ser-His-Asp-Gly-Tyr-Cys-Leu-His-Asp-Gly-Val-Cys-Met-Tyr-Ile-Glu-Ala-Leu-Asp-Lys-Tyr-Ala-Cys-Asp(NH,)-Cys-Val-Val-Gly-Tyr-Ile-Gly-Glu-Arg-Cys-Glu(NH,)Tyr-Arg-Asp-Leu-Lys-OH. The rhEGF,.,, concentration and activity were determined by high-power liquid chromatography and tritiated thymidine uptake by mouse 3T3 fibroblasts. Placebo was 20 mM phosphate buffer containing 0.05% Tween 80 (pH 6.09).
Experimental animals
Male and female adult Wistar rats (Crl;[WI]BR@) approximately 3-4 months of age were obtained from Charles River Breeding Laboratories (Kingston, NY). Animals were housed in polycarbonate shoe-box cages containing absorbent bedding, were fed Purina Certified Rodent Chow@ during acclimation and testing periods, and were offered water ad libitum. Animals were assigned to dosage groups with a computer-assisted randomization p r o c e d~r e .~~
Experimental design
Treatment groups of at least 12 animals were given 0, 25, 100, or 250 pdkg of rhEGF,,, daily for 4 weeks by continuous intravenous infusion. Following general anesthesia induced with a ketamine, xylazine, and acetylpromazine mixture, an intravenous catheter was placed in the jugular vein. A tether and jacket apparatus was used to prevent damage or removal of the catheter. Benzathine penicillin was administered subcutaneously at 30,000 U/kg 48 hours prior to the initiation of drug administration to prevent postsurgical infection. Rats were allowed to recover for 3-5 days prior to the initiation of dosing. Dosing solutions were administered intravenously on a microgram/kilogram body weight basis at a rate of approximately 200 pl/hour using Harvard digital syringe infusion pumps. Because of their deteriorated condition, males and females given 250 pdkg were euthanatized during the final week of dosing (days 21-26), prior to the completion of the 28-day dosing period. During the course of the study, animals were observed daily for signs of toxicity and systemic effects; body weights were recorded pretest, weekly, and at termination. Treatment group size was not uniform at study termination because several animals in various groups were omitted from the study because of catheterization complications.
Clinical laboratory tests
Red cell count, white cell count (total and differential), mean corpuscular hemoglobin concentration, hemoglobin, hematocrit, mean corpuscular volume, and mean corpuscular hemoglobin were determined at study termination. Serum samples were analyzed for urea nitrogen, creatinine, alanine aminotransferase, glucose, protein, gastrin, bilirubin, cholesterol, phosphorus, potassium, calcium, chloride, sodium, lactate dehydrogenase, alkaline phosphatase, and aspartate aminotransferase. Bone marrow samples, obtained at necropsy, were evaluated for total nucleated cell counts and cell differential counts.
Pathology
Complete necropsies were performed on all rats found dead, euthanatized moribund, or euthanatized at study termination. Rats were euthanitized by carbon dioxide inhalation. Brain, pituitary, thyroid, adrenal glands, liver, submandib-ular salivary glands, lungs, heart, thymus, spleen, kidneys, gonads, uterus, prostate, and epididymides weights were recorded at termination. Organ-to-body and organ-to-brain weight ratios were calculated. Representative specimens from all major tissues were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 4-5 pm, and stained with hematoxylin and eosin. Gross pathology and histopathologic data analysis included only those animals that were euthanatized at the end of the study.
Statistical management of data
All group differences except organ weight and bone marrow were tested in pairwise comparison with controls by applying the two-tailed Student's t-test at a probability level of 0.99. For organ weight and bone marrow data, treatment comparisons were performed on rank-transformed data using a one-factor analysis of variance (ANOVA), focusing on a dose trend sequentially applied at the two-tailed 1% significance level.
Results
Clinical signs
Clinical signs were nonspecific and included chromodacryorrhea, dehydration, lacrimation, red staining around the nose, rough pelage, and hypoactivity. Although the signs were attributed to tethering and mode of drug administration, their incidence was dose related, suggesting that the drug exacerbated these effects. After day 14, the incidence and severity of dehydration, hypoactivity, and rough pelage increased, and the 250-yg/kg animals were euthanatized during the final week of dosing. Two lOO-yg/kg males were euthanatized in a moribund state on days 21 and 28. Several additional animals were euthanatized because of catheterization complications early in the study that were not related to treatment effect.
Body weights and food consumption
Mean body weight of the 250-pglkg males was significantly decreased relative to the controls by 8.9%, 1 l.8%, and 15.9% in weeks 2, 3, and 4, respectively.
When euthanatized, the 250-yglkg males had lost 1.5% of their initial body weight. No other significant differences in mean body weights were observed in drugtreated animals, although body weight gain of the 100yglkg males to week 4 was significantly decreased by 73% relative to the controls. No significant changes in food consumption were seen in either sex.
Clinical laboratory tests
No clinically significant alterations were seen in hematologic parameters of drug-treated males. Females administered 100 and 250 yglkg had approximately a 9% decrease in erythrocyte count. The counts of bone marrow total nucleated cells were reduced 43% in males administered 250 yglkg. Myeloid cells were 40% lower Vet Pathol33:2, 1996 Table 1 . Incidence summary* of significant gross changes in rats administered recombinant human epidermal growth factor,.,, and euthanatized at the end of the study. than control males, and erythroid cells were decreased by 53% in these drug-treated animals. Although not statistically significant, the lymphocyte count in males treated with 250 pg/kg was 43% lower than that of control. No significant alterations in bone marrow parameters were seen at 25 or 100 pg/kg in males. Females showed a similar pattern of bone marrow changes, with significant decreases in counts of total nucleated cell, myeloid cells, erythroid cells, and lymphocytes at both 100 and 250 pg/kg. No significant bone marrow changes were seen in females administered 25 pg/kg. The most significant change in serum chemistry was a 4-5-fold increase over controls in gastrin levels in males given 250 pg/kg. Females administered 250 pg/ kg had gastrin concentrations 7.5 times those of controls. Alkaline phosphatase activity in both sexes was reduced 45-57% at 100 clg/kg and approximately 70% at 250 pg/kg.
Gross pathology
Treatment-related alterations evident at necropsy of rats euthanatized at the end of the study included Harderian gland and ovary enlargement, urinary bladder thickening, and chromodacryorrhea (Table 1) . Harderian glands were enlarged and the urinary bladder was thickened in both sexes at an incidence that was dose related. Ovarian enlargement was also observed, but the incidence was not consistently dose related. The treated males also had dose related increases in chromodacryorrhea.
Organ weight changes
Submandibular salivary gland weights were increased approximately 25% in both sexes at 100 and 250 pg/kg. Liver-to-brain weight ratios were also increased 13% in the 250-pg/kg males and in females at 100 (1 4% increase) and 250 (29% increase) p.g/kg. Kidney-to-body weight ratios were increased 26% in females at 250 pg/kg. Ovary-to-brain weight ratios were increased 3 1-94% in treated females at all doses. Thymus-to-brain weight ratios were decreased 36% in the lOO-pg/kg and 26% in the 250-pg/kg males.
Histopathology
Drug-induced epithelial hyperplasia occurred in a dose-dependent manner in the stomach, small intestine, large intestine, prostatic urethra, urinary bladder, renal pelvis and collecting ducts, seminal vesicle, trachea, nasal cavity, nasal lacrimal duct, tongue, tooth enamel organ, submandibular salivary gland ducts, and Harderian gland (Table 2 ). Gastric glandular mucosal and intestinal epithelial proliferation ( Fig. 1) were characterized by increased mucosal thickness, expanded proliferative zone of gastric glands and intestinal crypts, increased density of cells, decreased cellular differentiation, increased cytoplasmic basophilia, and a higher nucleus : cytoplasm ratio. In addition, gastric lamina propria was expanded due to edema and increased loose connective tissue. Nonglandular gastric mucosa was thickened and had an expanded keratinized layer. Hepatocellular hypertrophy, occurring at 100 and 250 pg/kg, was restricted to periportal areas and coexisted with other cytologic changes, which included anisokaryosis, occasional binucleate cells, and increased cytoplasmic eosinophilia. The lingual mucosal hyperplasia in the 25O-pglkg animals consisted of diffuse uniform thickening of the mucosa epithelial layers and 2-3-fold thickening of the keratinized layer.
The renal pelvis, urinary bladder (Fig. 2) , and prostatic urethra had moderately to markedly thickened urothelial mucosa and occasional low-profile papilliferous projections in high-dose groups; urothelium mitoses were apparent but not common. In conjunction with the renal pelvis urothelial hyperplasia, the collecting ducts were lined by hyperplastic epithelium with increased number of cells per duct cross section, increased epithelial cytoplasmic eosinophilia, and mild duct luminal dilatation (Fig. 3) .
The tracheal mucosal changes consisted of mild mucosal thickening, increased cellular density, decreased cellular differentiation, and higher nucleus : cytoplasm ratio. The respiratory epithelium of the nasal cavity was hyperplastic at 250 pg/kg. The response was most prominent in the dorsal rostra1 turbinate areas where the epithelium was 2-3-fold thicker than that of controls, with formation of occasional intramucosa pseudoglandular structures (Fig. 4) . The diffuse epithelial hyperplasia in the nasal lacrimal duct was characterized by variably thickened mucosa, higher nucleus : cytoplasm ratio, loss of cilia, and occasional pyknotic nuclei ( Fig. 5) . At 250 fig/kg, ameloblastic epithelium in the enamel organ of the tooth was hyperplastic, as indicated by increased density of cells (pseudostratified appearance), increased nucleus : cytoplasm ratio, increased cytoplasmic eosinophilia, and decreased cytoplasmic volume; cells in the underlying stellate reticulum were also hyperplastic. Harderian gland alterations were characterized by increased number of epithelial cells per acini, increased cell size, accumulation of cell debris in acinar lumina, focal areas of brown pigmentation, and occasional areas of degenerative cells with pyknotic nuclei (Fig. 6) . Dose related nonepithelial cell proliferation was also seen as heart valve thickening, glandular stomach lamina propria edema/fibrosis (lamina propria), increased numbers of ovarian corpora lutea, perineural perivascular hypercellularity adjacent to the sciatic nerve, and to a lesser extent splenic extramedullary hematopoiesis. The increased number of corpora lutea and luteal cysts correlated with the increased ovarian weights. The cardiac valvular connective tissue proliferation was characterized as variably thickened valves (aortic, pulmonary, atrioventricular) due to accumulation of loose connective tissue populated by mesenchymal cells with dark elongate nuclei (Fig. 7) . The increased connective tissue involved predominantly the valvular leaflets; however, the mesenchymal proliferation also extended to the base ofthe valves, adjacent endocardia1 interstitium, and along chordae tendineae.
Discussion
Unlike other studies that have described EGF-induced changes in selective rat tissues, we have detailed the morphologic effects in all body systems following continuous intravenous infusion of exogenous growth factor. The rhEGF,,, treatment did not result in deaths; however, rats at 250 pg/kg became moribund due to dehydration and hypoactivity. The rhEGF,,, was well tolerated in the 25and lOO-pg/kg treatment groups; body weight and spontaneous activity decreased only in the 250-pg/kg treatment group. The elevation of gastrin in the 250-pg/kg males and females was unexpected because in previous studies involving neonatal rats,9 dogs,29 and humansIo EGF treatment did not result in elevated serum gastrin. However, an in vitro study demonstrated that EGF increased the rate of gastrin transcription in GH4 pituitary cells transfected with constructs of the first exon of the human gastrin gene and various lengths of regulatory sequenc-e~. '~ The rhEGF,,, treatment resulted in both gastric and intestinal mucosal epithelial proliferation, as predicted Breider, Bleavins, Reindel, Cough, and de la Iglesia Urinary bladder; rat. Fig. 2a . Control rat. Bar = 100 pm. Fig. 2b . Rat treated with 250 pdkg rhEGF,,,. Note increased mucosa thickness. Bar = 100 pm. Renal papillae; rat. Fig. 3a . Control rat. Bar = 38 pm. Fig. 3b . Rat treated with 250 pdkg rhEGF,.,,. Note hyperplasia of collecting duct epithelium characterized by increased cell density and increased nucleus : cytoplasm ratio. Bar = 38 pm. Vet Pathol 33:2, 1996 5b Fig. 4. Nasal cavity; rat. Fig. 4a . Control rat. Bar = 63 pm. Fig. 4b . Rat treated with 250 pglkg rhEGF,.,,. Note Harderian gland; rat. Fig. 6a . Control rat. Bar = 100 pm. Fig. 6b . Rat treated with 250 pg/kg rhEGF,,,. Note epithelial hypertrophy and anisokaryosis, occasional acinar cells with pyknotic nuclei, and intra-acinar cell debris. Bar = 100 pm. Fig. 7 . Mitral cardiac valve; rat. Fig. 7a . Control rat. Bar = 357 pm. Fig. 7b . Rat treated with 250 pdkg rhEGF,,,. Note thickened valve due to increased mesenchymal tissue. Bar = 357 pm. Vet Path01 33:2, 1996 by earlier studies in rats,11,22,39 except for one previous study that did not demonstrate gastric mucosal proliferation. I The EGF-induced gastric mucosal proliferation in rats has also been documented previously with increased DNA ~y n t h e s i s~,~.~~ and increased gastric mucosal ' but no corresponding histopathologic evaluation was available. The expanded proliferative zone in the gastric mucosa suggests that mucosal function could be altered because of the less differentiated nature of epithelial cells. A previous study of unweaned rats (10-1 5 days of age) showed that EGF stimulates gastric oxyntic mucosal growth without leading to precocious maturation or functional devel-~p m e n t .~ Both the small and large intestine in the 100-and 250-pg/kg rhEGF,,,-treated rats had mucosal hyperplasia characterized by increased crypt epithelium and thickened mucosa, in agreement with previous studies using the complete growth f a~t 0 r . I~~~~ In one study, continuous intravenous infusion of 15 pgkg recombinant beta urogastrone (EGF) in rats resulted in increased intestinal cell proliferation and intestinal tissue weights throughout the gastrointestinal tract, whereas urogastrone administered through an intragastric cannula had no effect on intestinal pr01iferation.l~ In another study, the intraluminal administration of EGF ( 5 pglanimal purified from mouse salivary gland) into the ileum of adult rats resulted in ileal mucosal proliferation, indicated by increased mucosal ornithine decarboxylase specific activity, mean DNA specific activity, mean DNA content, and crypt labeling index. 47 Another study in adult rats demonstrated colonic growth in normal adult rats administered subcutaneous infusions of 200 pg/kg rhEGF for 7 days; however, an 80-fold higher dose of intraluminal EGF had no colonic proliferative
The intestinal proliferative effects of intravenous or subcutaneously administrated EGF were verified in an experimental colitis model in the rat30 and in a surgically defunctioned distal colorectum. l 2
The other alimentary tract epithelial organs affected by the rhEGF,,, treatment in our study included salivary glands, tooth enamel organ, tongue, and liver. The salivary gland is reputed to be a major source of EGF in the b~d y~,~ and to serve as an important mitogenic influence of the alimentary tract as a growth promotant and cytoprotective agent. 28 Immunocytochemical localization has demonstrated EGF in Brunner's glands and the submandibular salivary glands, Paneth cells of the small intestine, and tubular cells of the kidney. 37 Our results demonstrated predominantly a proliferation of salivary gland ductular epithelium without evident acinar cell hyperplasia. Previous in vivo studies have implied EGF-induced salivary gland acinar cell proliferation by measuring increased ex-pression of beta 1-4 galactosyltransferase in rats', but did not directly stimulate increased DNA synthesis in the salivary glands of mice.2o The proliferation of ameloblasts in the growing incisors of rhEGF,,,-treated rats in our study is supported by results of a previous study demonstrating localization of epidermal growth factor receptors in cells ofthe enamel organ, specifically in ameloblast and papillary layer cells. 32 The lack of rhEGF,,,-induced pancreatic acinar or ductal proliferation in our study was consistent with a previous in vivo study in which rats treated with mouse EGF did not exhibit any increase in pancreatic weight or protein content and in fact had an inhibited DNA incorporation rate and decreased DNA content of the pancreas. 34 Subcutaneous infusion of rhEGF stimulated pancreatic protein secretion after 4 hours, suggesting a modulatory role of EGF on pancreatic secretory function.21 This function hypothesis is further supported by the demonstration of EGF binding sites on acinar pyramidal cells, intercalated duct cells, and cells of the islets of Langerhans. 6 The rhEGF,,,-induced periportal hepatocellular hypertrophy was of a lesser magnitude than we expected, considering previous reports describing EGF effects on rat hepatocytes. The periportal distribution of hepatocellular hypertrophy we observed is consistent with predicted EGF-responsive cell populations. Previous studies in rats have demonstrated that intravenous rat EGF preferentially binds to hepatocytes located in the periportal area, and there is a steep portal-to-central lobular concentration gradient for EGF ~p t a k e .~,~~ Although the hepatic parenchymal tissue following rhEGF,,, treatment did not exhibit increased mitotic index, the anisokaryosis, expanded cell size, and increased cytoplasmic eosinophilia indicate EGF-stimulated hepatocellular activity, presumably similar to that in previous reports of EGF-induced increases in ribosomal RNA. 45 Urothelial hyperplasia of the renal pelvis, urinary bladder, and prostatic urethra was an index of tissue sensitivity in our study, consistent with presumed urinary clearance of EGF and EGF-binding sites in the k i d n e~.~~,~~ EGF-related changes in the medullary collecting ducts and pelvic urothelium were more pronounced than in cortical tubules. This distribution is surprising, considering that a previous study demonstrated that the relative density of EGF binding sites in the kidney was greatest in the cortex followed by the inner medulla and finally the outer medulla.26 These binding sites included high-affinity binding sites on the antiluminal cell surface membrane for uptake of circulating EGF2' and low-affinity binding sites on the luminal cell surface for reabsorption of filtered EGF. 26 Although tracheal epithelial hyperplasia occurred in our study, epithelial changes in the lung were not ap-parent, consistent with previous reports of a very low amount of EGF binding in the rat The nasal cavity epithelial hyperplasia in our study was much more pronounced than that in other respiratory mucosa. This change was concurrent with Harderian gland and nasal lacrimal duct epithelial hyperplasia. The Harderian gland may have an important role in the clearance of circulating EGF by secretion into the ocular fluid and subsequent drainage in the nasal lacrimal duct. It was surprising that corneal epithelial hyperplasia was not induced in EGF-treated rats, considering that previous studies have demonstrated EGFenhanced corneal healing in feline43 and rabbit3 corneal injury models. The mechanism of the heart valve thickening is uncertain. Other studies have shown that EGF may induce proliferation of rat smooth muscle cells and dermal fibroblasts in v i t r~,~~ but the response of cardiac valve mesenchymal cells to E G F has not been reported.
In our study male rats were more sensitive than female rats to the proliferative effects of rhEGF,.48, as indicated by the higher incidence of epithelial hyperplasia in the male low-dose group. In one previous in vitro study, hepatocytes isolated from male rats were much more responsive to the mitogenic effects of EGF than were hepatocytes isolated from female rats, in part because of the lower number of high-affinity receptors for EGF in female hepatocyte~.'~ Unfortunately, previous in vivo studies reporting EGF binding capacity of various tissues were not done concurrently in female and male rats.
The results of this study verify that rhEGF,,, can induce epithelial proliferation in many organ systems in the rat, and even extremely high doses of rhEGF,.,, can be well tolerated clinically. The rhEGF,,, may have future therapeutic application of a presumed higher efficacy in human trials because of closer affinity of rhEGF,,, to human tissue EGF receptors.
